• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Ver­tan­i­cal’s Phase 3 win for non-opi­oid painkiller; Apri­ori lays off 40% of staff 

2 months ago
News Briefing

Post-Hoc: Kennedy's an­ti-vac­cine ac­tions should­n't sur­prise any­one

2 months ago
Pharma
FDA+

George Church spin­out de­vel­op­ing ge­nom­i­cal­ly re­cod­ed or­gan­isms cuts most em­ploy­ees

2 months ago
People
Startups

Cure­vo gets $110M for a shot against Shin­grix, gets Mon­cef Slaoui and Tal Zaks on board

2 months ago
Financing
Startups

Ot­suka's Tai­ho buys Swiss start­up Araris with three AD­Cs near­ing the clin­ic

2 months ago
Startups
Deals

As­traZeneca spot­lights first-in-hu­man da­ta for B7-H4-tar­get­ing ADC in en­dome­tri­al can­cer

2 months ago
R&D

HC Bio­science, a tR­NA biotech backed by ARCH and Take­da, shuts down

2 months ago
People
Startups

Avid­i­ty seeks to 'set the stan­dard' as it heads to FDA with Duchenne drug

2 months ago
R&D
Pharma

As­traZeneca to buy cell ther­a­py start­up for $425M up­front

2 months ago
Deals
Cell/Gene Tx

Lati­go col­lects $150M to get non-opi­oid da­ta to com­pete with Ver­tex in acute pain

2 months ago
Financing
Startups

Lil­ly-backed UK biotech rais­es $72M to ad­vance its an­ti­body ap­proach

2 months ago
Financing
Startups

Up­dates on health agency nom­i­nees; New da­ta from Pfiz­er, Beam; MASH start­up weighs IPO; and more

2 months ago
Weekly

'It’s the law’: Dr. Oz says he would de­fend Medicare drug price ne­go­ti­a­tions

2 months ago
Pharma
FDA+

Fed­er­al Cir­cuit rul­ing al­lows Am­gen's Eylea biosim­i­lar to stay on the mar­ket

2 months ago
Pharma
Law

Boston Phar­ma, build­ing off MASH mo­men­tum, mulls an IPO ahead of Phase 3 tri­al

2 months ago
R&D

UK's plan to hike drug­mak­er re­bates re­flects 'bro­ken' sys­tem, phar­ma group says

2 months ago
Pharma

Re­ci­pharm hits record rev­enue for 2024, eyes GLP-1 con­tracts for growth 

2 months ago
Pharma
Manufacturing

RFK Jr. con­vened round­table around ways to re­duce stem cell reg­u­la­tion

2 months ago
Pharma
Cell/Gene Tx

Al­tim­mune to put its in­cretin in­to ad­dic­tion tri­als; Tar­sus aims to raise $125M

2 months ago
News Briefing

Sutro slash­es work­force in half, changes CEO and clos­es fac­to­ry

2 months ago
People
Pharma

Mer­ck di­ver­si­ty leader to re­tire this sum­mer; Geron seeks com­mer­cial chops for next CEO

2 months ago
Peer Review

Lil­ly-part­nered Fau­na Bio plans $40M Se­ries A to get in­to heart fail­ure

2 months ago
Financing
Startups

Moon­Lake's CEO on its loom­ing mid-year piv­otal read­out in skin dis­ease

2 months ago
Pharma

Pfiz­er ter­mi­nates an ear­ly-stage STING ag­o­nist tri­al

2 months ago
R&D
Pharma
First page Previous page 23242526272829 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times